Highest-materiality recent filing
Sera Prognostics Q1 revenue minimal at $14K; PRIME trial shows 56% reduction in early preterm births
Q1 2026 revenue $14,000 vs $38,000 YoY; net loss $8.4M vs $8.2M; operating expenses $9.4M.
Sera Prognostics Q4 net loss $7.9M; PRIME study shows 56% reduction in preterm births <32 wks
Q4 2025 net loss $7.9M vs $8.6M Q4 2024; full-year net loss $31.9M vs $32.9M.
PRIME study: PreTRM blood test cuts preterm births <32 wks by 56%, NICU admissions by 20%
Randomized trial of 5,018 women: 56% fewer births <32 wks, 32% fewer <35 wks.
Sera Prognostics Q4 revenue $24k; PRIME study meets primary endpoints; raised $57.5M
Q4 2024 revenue $24,000; net loss $8.6M vs $7.9M prior year.
Sera Prognostics prices $50M public offering of 1.25M shares and 11.25M pre-funded warrants
Offering priced at $4.00 per share of Class A common stock and $3.9999 per pre-funded warrant.
Sera Prognostics PRIME study meets both co-primary endpoints; cash $68.2M
Cash, cash equivalents, and marketable securities were approximately $68.2 million as of December 31, 2024 (preliminary).
Sera Prognostics PRIME study topline results published by SMFM
SMFM published an abstract of topline results for the PRIME study on preterm birth risk assessment.
Jeffrey T. Elliott, a member of the Board of Directors (the “Board”) of Sera Prognostics, Inc. (the “Company”), notified the Company of his decision to resign from the Board effective as of June 4, 2026
Max materiality 0.85 · Median 0.50 · Most common event other_material